Ten63’s deal with Boehringer; Coya sets up agree­ment with Dr. Red­dy’s; Re­NA­gade’s lay­offs

Ten63 Ther­a­peu­tics’ drug dis­cov­ery deal with Boehringer In­gel­heim: The Durham, NC-based start­up, which is us­ing gen­er­a­tive AI to de­vel­op small mol­e­cule med­i­cines, said the agree­ment spans mul­ti­ple tar­gets and dis­ease ar­eas. Fi­nan­cial de­tails weren’t dis­closed. Ten63 in May an­nounced a $15.9 mil­lion Se­ries A and plans to de­vel­op drugs that tar­get the in­fa­mous c-Myc, a pro­tein fre­quent­ly im­pli­cat­ed in pan­cre­at­ic can­cer. A pre­vi­ous­ly undis­closed in­vestor from that round is Yosemite, the can­cer-fo­cused ven­ture cap­i­tal fund re­cent­ly launched by Reed Jobs, whose fa­ther and Ap­ple co­founder Steve Jobs died from pan­cre­at­ic can­cer. — Ryan Cross

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER